Abbott Laboratories (ABT)
| Previous close | 106.86 |
| Open | 106.51 |
| Bid | 107.41 x 800 |
| Ask | 107.40 x 800 |
| Day's range | 106.42 - 107.59 |
| 52-week range | 89.67 - 121.64 |
| Volume | |
| Avg. volume | 5,831,382 |
| Market cap | 186.41B |
| Beta (5Y monthly) | 0.74 |
| PE ratio (TTM) | 33.47 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 2.20 (2.06%) |
| Ex-dividend date | 12 Apr 2024 |
| 1y target est | N/A |
- PR Newswire
Abbott Reports First-Quarter 2024 Results and Raises Midpoint of Full-Year Guidance Ranges
Abbott (NYSE: ABT) today announced financial results for the first quarter ended March 31, 2024.
- PR Newswire
Abbott Receives FDA Approval for TriClip™, First-of-Its-Kind Device to Repair Leaky Tricuspid Heart Valve
Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has approved the company's first-of-its-kind TriClip™ transcatheter edge-to-edge repair (TEER) system that's specifically designed for the treatment of tricuspid regurgitation (TR), or a leaky tricuspid valve. This approval follows the recent recommendation of the Circulatory System Devices Panel of the Medical Devices Advisory Committee for the FDA, whose vote confirmed 13 to 1, with 0 abstention that the benefi
- PR Newswire
Abbott Receives FDA Clearance for Whole Blood Rapid Test to Help with Assessment of Concussion at the Patient's Bedside
Abbott's i-STAT TBI cartridge has received clearance from the U.S. Food and Drug Administration (FDA) to be used with whole blood, allowing doctors to help assess patients with suspected concussion at the patient's bedside and obtain lab-quality results in 15 minutes. Previously, the tests to help with the assessment of TBI were only cleared for use with plasma or serum, requiring samples to be sent to a lab for processing and testing.
